Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

CYTALUX

PAFOLACIANINE SODIUM

Standard Dose
EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview CYTALUX is listed in Drugs@FDA under application 214907 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient PAFOLACIANINE SODIUM Form and strength SOLUTION;INTRAVENOUS - EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML) Sponsor ON TARGET LABS Submission history Latest submission status date: 2022-12-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview CYTALUX is listed in Drugs@FDA under application 214907 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient PAFOLACIANINE SODIUM Form and strength SOLUTION;INTRAVENOUS - EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML) Sponsor ON TARGET LABS Submission history Latest submission status date: 2022-12-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.